Major Indexes

Financial Summary

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Limi... (TEVA)

0.105 (+0.89%)
Market Info
Financial Info
Financial Modelling
Symbol TEVA
Price 11.865$
Beta 1.84
Volume Avrg. 10.87M
Market Cap 12.62B
Shares (2019) 1,091,000.00K
Last Div 0
Dividend Yield 0.43%
DCF Unlevered -
DCF Levered -
ROE -7.15% Neutral
ROA -1.74% Neutral
Operating Margin -2.62% Neutral
Debt / Equity 311.32% Strong Buy
P/E -11.22 Strong Sell
P/B 0.80 Buy

Income Statement

Quarter data
Download TEVA income statement Download TEVA income statement Download TEVA income statement
Year 2019 2018
Earnings Per Share Diluted -2.35-0.91
Net Profit Margin -0.11-0.06
Weighted Average Shares Outstanding 0.001,091.00
Revenue 18,854.0016,887.00
Weighted Average Shares Outstanding (Diluted) 0.001,091.00
Gross Profit 8,296.007,537.00
Dividend per Share --
Operating Income -1,637.00-443.00
Gross Margin 0.440.45
Income Tax Expense -195.00-278.00
EBIT Margin 0.010.08
Net Income -2,150.00-999.00
Cost of Revenue 10,558.009,351.00
Earnings Before Tax Margin -0.16-0.07
EBIT -1,637.00-443.00
EBITDA 205.001,279.00
Profit Margin -0.11-0.06
Operating Expenses 5,427.004,816.00
Earnings Per Share Basic -2.35-0.91
Earnings before Tax -3,057.00-1,265.00
Interest Expense 920.00881.00

Balance Sheet Statement

Quarter data
Download TEVA balance shet statement Download TEVA balance sheet statement Download TEVA balance sheet statement
Year 2019 2018
Short-term debt 2,216.002,345.00
Other Assets 1,099.001,492.00
Total current liabilities 14,322.0013,674.00
Cash and cash equivalents 1,782.001,975.00
Long-term debt 26,700.00435.00
Cash and short-term investments 1,782.001,975.00
Total debt 28,916.002,780.00
Inventories 4,731.004,422.00
Deferred revenue 368.00386.00
Goodwill and Intangible Assets 38,922.0036,078.00
Total non-current liabilities 30,567.0028,733.00
Total non-current assets 46,889.0044,006.00
Total liabilities 45,976.0043,498.00
Total assets 60,683.0057,470.00
Other comprehensive income 23,068.0023,184.00
Short-term investments 991.00957.00
Property, Plant & Equipment Net 6,868.006,436.00
Net Debt 27,134.00805.00
Investments 991.00957.00
Total shareholders equity 14,707.0013,972.00
Retained earnings (deficit) -5,958.00-6,956.00
Long-term investments --
Receivables 5,822.005,676.00
Payables 1,853.001,718.00
Total current assets 13,794.0013,464.00

Cash Flow Statement

Quarter data
Download TEVA cash flow statement Download TEVA cash flow statement Download TEVA cash flow statement
Year 2019 2018
Investing Cash Flow 1,724.001,355.00
Free Cash Flow 1,795.00223.00
Depreciation & Amortization 1,842.001,722.00
Net cash flow / Change in cash 819.00193.00
Effect of forex changes on cash -142.0016.00
Financing Cash Flow -3,351.00-1,926.00
Dividend payments -12.00-52.00
Stock-based compensation 155.00119.00
Investment purchases -119.00-8.00
Acquisitions and disposals --
Capital Expenditure 651.00525.00
Operating Cash Flow 2,446.00748.00

Retained Earning Schedule

Year 2018 2019
Retained Earnings (Previous Year) -3,803-5,958
Net Income -2,150-999
Stock Dividends 753
Dividend Paid -12-52
Retained Earnings -5,958-6,956

PPE Schedule

Year 2018 2019
Gross PPE 7,6736,868
Annual Depreciation -1,456-957
Capital Expenditure 651525
Net PPE 6,8686,436

Intangible and Goodwill Schedule

Year 2018 2019
Intangible and Goodwill (Previous Year) 46,05438,922
New Purchases -119-8
Intangible and Goodwill 38,92236,078


Mr. Kre Schultz
Drug ManufacturersSpecialty & Generic
New York Stock Exchange

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick